BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
Taking everything into account, BBIO scores 2 out of 10 in our fundamental rating. BBIO was compared to 564 industry peers in the Biotechnology industry. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative. BBIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BBIO has reported negative net income.
In the past year BBIO has reported a negative cash flow from operations.
BBIO had negative earnings in each of the past 5 years.
In the past 5 years BBIO always reported negative operating cash flow.
1.2 Ratios
BBIO has a Return On Assets of -66.00%. This is in the lower half of the industry: BBIO underperforms 63.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-83.5%
ROA(5y)-71.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BBIO's Gross Margin of 98.90% is amongst the best of the industry. BBIO outperforms 98.38% of its industry peers.
In the last couple of years the Gross Margin of BBIO has declined.
BBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.67%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBIO has been increased compared to 1 year ago.
The number of shares outstanding for BBIO has been increased compared to 5 years ago.
The debt/assets ratio for BBIO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.04, we must say that BBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.04, BBIO is not doing good in the industry: 66.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.04 |
ROIC/WACCN/A
WACC9.87%
2.3 Liquidity
A Current Ratio of 3.19 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a worse Current ratio (3.19) than 62.12% of its industry peers.
A Quick Ratio of 3.19 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a Quick ratio of 3.19. This is in the lower half of the industry: BBIO underperforms 60.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.19 | ||
| Quick Ratio | 3.19 |
3. Growth
3.1 Past
BBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.05%, which is quite impressive.
The Revenue has grown by 2209.28% in the past year. This is a very strong growth!
Measured over the past years, BBIO shows a small growth in Revenue. The Revenue has been growing by 4.09% on average per year.
EPS 1Y (TTM)32.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.85%
Revenue 1Y (TTM)2209.28%
Revenue growth 3Y4.09%
Revenue growth 5YN/A
Sales Q2Q%-33.22%
3.2 Future
BBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.95% yearly.
Based on estimates for the next years, BBIO will show a very strong growth in Revenue. The Revenue will grow by 161.37% on average per year.
EPS Next Y32.14%
EPS Next 2Y2.11%
EPS Next 3Y7.95%
EPS Next 5Y16.95%
Revenue Next Year1622.06%
Revenue Next 2Y276.51%
Revenue Next 3Y217.51%
Revenue Next 5Y161.37%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.11%
EPS Next 3Y7.95%
5. Dividend
5.1 Amount
BBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRIDGEBIO PHARMA INC
NASDAQ:BBIO (1/3/2025, 8:21:43 PM)
After market: 28.14 +0.02 (+0.07%)28.12
-0.08 (-0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners75.64%
Inst Owner Change-1.07%
Ins Owners4.81%
Ins Owner Change-154.41%
Market Cap5.31B
Analysts81.82
Price Target50.14 (78.31%)
Short Float %11.43%
Short Ratio8.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.93%
Min EPS beat(2)-10.2%
Max EPS beat(2)64.07%
EPS beat(4)2
Avg EPS beat(4)31.21%
Min EPS beat(4)-10.2%
Max EPS beat(4)74.34%
EPS beat(8)2
Avg EPS beat(8)8.17%
EPS beat(12)4
Avg EPS beat(12)11.96%
EPS beat(16)5
Avg EPS beat(16)5.39%
Revenue beat(2)0
Avg Revenue beat(2)-34.63%
Min Revenue beat(2)-40.46%
Max Revenue beat(2)-28.8%
Revenue beat(4)1
Avg Revenue beat(4)308.28%
Min Revenue beat(4)-72.53%
Max Revenue beat(4)1374.92%
Revenue beat(8)1
Avg Revenue beat(8)134.97%
Revenue beat(12)2
Avg Revenue beat(12)102.32%
Revenue beat(16)3
Avg Revenue beat(16)62.2%
PT rev (1m)3.12%
PT rev (3m)1.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-542.61%
EPS NY rev (1m)-13.18%
EPS NY rev (3m)-49.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-98.63%
Revenue NY rev (1m)-12.43%
Revenue NY rev (3m)-42.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 24.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.65
EYN/A
EPS(NY)-3.77
Fwd EYN/A
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS1.15
BVpS-6.51
TBVpS-6.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.9% | ||
| FCFM | N/A |
ROA(3y)-83.5%
ROA(5y)-71.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.67%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 97.06% | ||
| Cap/Sales | 2.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.19 | ||
| Quick Ratio | 3.19 | ||
| Altman-Z | -6.04 |
F-Score4
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)113.45%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.73%
Cap/Sales(5y)29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.85%
EPS Next Y32.14%
EPS Next 2Y2.11%
EPS Next 3Y7.95%
EPS Next 5Y16.95%
Revenue 1Y (TTM)2209.28%
Revenue growth 3Y4.09%
Revenue growth 5YN/A
Sales Q2Q%-33.22%
Revenue Next Year1622.06%
Revenue Next 2Y276.51%
Revenue Next 3Y217.51%
Revenue Next 5Y161.37%
EBIT growth 1Y2.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.59%
EBIT Next 3Y8.19%
EBIT Next 5Y14.83%
FCF growth 1Y2.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.16%
OCF growth 3YN/A
OCF growth 5YN/A